Artificial Intelligence

Documents

FDA

Reference 5 - Concentration-Dependent Bidirectional Modification of Evoked Synaptic Transmission by Gadolinium

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 6 - Literature case analysis of nephrogenic systemic fibrosis induced by gadolinium-based contrast agents

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 7 - Incorporation of excess gadolinium into human bone from medical contrast agents

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 8 - Repeated gadolinium

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 9 - Gadolinium Mitochondrial Toxicity

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 10 - Gadolinium-Based Contrast Agent Accumulation and Toxicity

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 11 - On the interaction of muscle actin with gadolinium

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 12 - Skin-Related Adverse Reactions in Gadolinium-Based Contrast Agents-Induced Hypersensitivity

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 13 - Prepubertal exposure to gadolinium

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 14 - Contrast-free identification of glioma blood-brain barrier status via generative diffusion AI and non-contrast MRI

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 15 - Gadolinium based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →
FDA

Reference 16 - Immediate adverse reactions to gadolinium-based MR contrast

0 comments

Analysis in progress

Top issues in comments

Not yet determined
Read the record →